Imported disease screening prior to chemotherapy and bone marrow transplantation for oncohematological malignancies

Adrián Sánchez-Montalvá, Fernando Salvador, Isabel Ruiz-Camps, Pere Barba, David Valcárcel, Elena Sulleiro, Enrique Sanz-García, Israel Molina

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)


Copyright © 2016 by The American Society of Tropical Medicine and Hygiene. Reactivation of latent imported infections has been periodically reported in migrant patients undergoing immunosuppression. We performed a prospective study at Vall d'Hebron University Hospital (Barcelona, Spain). Migrant patients over 16 years with the diagnosis of any oncohematologic disease were included. Patients were tested for soil-transmitted helminths, hepatitis virus, and human immunodeficiency virus, Treponema pallidum, human T-cell lymphotropic virus, latent tuberculosis infection, Toxoplasma spp., Plasmodium infection, Schistosoma spp., Trypanosoma cruzi infection, Leishmania spp., and dimorphic fungi. Patients were treated and followed for 1 year to assess reactivation. A total of 42 patients were included in this study. Median age was 39 (31-51) years. Twenty-five (59.5%) patients were women. More than half of the patients were of Latin American origin. Sixteen patients (38.1%) underwent hematopoietic stem cell transplantation. Of the patients, 71.4% had at least one imported infection. Patients with at least one positive result in the screening did not show any statistically significant association with the studied variables. We did not find any reactivation of the treated latent infections. After specific treatment we did not observe any reactivation. Screening of latent imported infections previous to an immunosuppressive treatment is easy to perform and it may be lifesaving.
Original languageEnglish
Pages (from-to)1463-1468
JournalAmerican Journal of Tropical Medicine and Hygiene
Issue number6
Publication statusPublished - 1 Dec 2016


Dive into the research topics of 'Imported disease screening prior to chemotherapy and bone marrow transplantation for oncohematological malignancies'. Together they form a unique fingerprint.

Cite this